Therapeutic combinations will have a higher chance of successful development against specific cancers that harbor both high TMB, increasing the chances of immune checkpoint inhibitors’ effectiveness and the target lesions of the drug(s) that is combined with them, such as PI3K inhibitors for cancers with PIK3CA mutations or PARP inhibitors for cancer with homologous recombination defects. Here, PIK3CA is linked to cancer.